Status: Recruiting
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Lapo AlinariUpdated: Feb 27, 2026Locations: 1
Eligibility criteria
Increased expression of MYC (>= 40%) and BCL2 (>= 50%) by immunohistochemistry (... [+21]
History of allergic reactions attributed to compounds of similar chemical or bio... [+14]